Page last updated: 2024-11-05

2-acetylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-acetylpyridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14286
CHEMBL ID11945
CHEBI ID193619
SCHEMBL ID55127
MeSH IDM0539610

Synonyms (78)

Synonym
629o10ui3l ,
unii-629o10ui3l
smr000112288
MLS002152864
1122-62-9
2-acetylpyridine
ethanone, 1-(2-pyridinyl)-
nsc15043
nsc-15043
2-pyridyl methyl ketone
methyl 2-pyridyl ketone
ketone, methyl 2-pyridyl
1-pyridin-2-ylethanone
NCGC00091706-01
2-acetylpyridine (natural)
ccris 7784
nsc 15043
einecs 214-355-6
2-acetopyridine
fema 3251
1-(2-pyridinyl)ethanone
ai3-52210
fema no. 3251
inchi=1/c7h7no/c1-6(9)7-4-2-3-5-8-7/h2-5h,1h
2-acetylpyridine, >=99%, fg
2-acetylpyridine, >=99%
acetylpyridine
A0111
CHEMBL11945 ,
CHEBI:193619
1-pyridin-2-yl-ethanone
bdbm50026891
AKOS000119795
A802529
1-(pyridin-2-yl)ethanone ,
NCGC00091706-02
1-(pyridin-2-yl)ethan-1-one
dtxsid7024409 ,
cas-1122-62-9
tox21_303104
NCGC00256952-01
dtxcid804409
NCGC00259050-01
tox21_201499
HMS2268O15
aqq7807jd8 ,
unii-aqq7807jd8
30440-88-1
STL145899
FT-0610981
AM20061676
AB00686
2-acetylpyridine [usp-rs]
2-acetylpyridine [fhfi]
SCHEMBL55127
acetyl pyridine
2-acetyl pyridine
2-acetyl-pyridine
1-(2-pyridyl)ethanone
1-(2-pyridinyl)ethanone #
Q-100067
ethanone, 1-(pyridinyl)-
1-(2-pyridyl)-1-ethanone
mfcd00006303
CS-W008602
F0001-0271
2-acetylpyridine, analytical standard
2-acetylpyridine, united states pharmacopeia (usp) reference standard
P19605
2-acetyipyridine
1-(2-pyridinyl)-ethanone
1-(2-pyridinyl)ethanone, 9ci
Q4596853
1-pyridin-2-ylmethanone
AS-14447
1-(pyridine-2-yl)ethanone
EN300-19607
Z104474432
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
GLI family zinc finger 3Homo sapiens (human)Potency32.03180.000714.592883.7951AID1259369; AID1259392
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.95260.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency39.81070.000214.376460.0339AID588532
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency51.08660.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.58670.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.19730.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency0.70790.707936.904389.1251AID504333
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency61.64480.001019.414170.9645AID743191
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.001419.739145.978464.9432AID1159509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki100.00000.00020.561410.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki100.00000.00020.635210.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki100.00000.00020.621710.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki100.00000.00020.675810.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki100.00000.00020.646910.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki100.00000.00020.671210.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki100.00000.00020.557710.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki100.00000.00020.640310.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki100.00000.00020.570810.0000AID40666
GABA theta subunitRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki100.00000.00020.656110.0000AID40666
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID40666In vitro inhibition of [3H]diazepam binding to benzodiazepine receptor in rat cerebral cortical membrane1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Beta-carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors.
AID208331Binding to stromelysin (MMP-3) in place of acetohydroxamic acid.2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.00)18.7374
1990's0 (0.00)18.2507
2000's3 (12.00)29.6817
2010's16 (64.00)24.3611
2020's5 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.20 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index60.89 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]